S

urrounding the DNA in all our cells are molecular systems that tell those genes when to turn on or off. As researchers learn more about these so-called epigenetic mechanisms, they’re increasingly looking to use them to modify problematic genes.

More than 20 drugs designed to block epigenetic proteins are in clinical trials now, following earlier drugs already on the market. And a new company aims to target one aspect of epigenetics — chromatin winding — to try to treat first cancer, and then other disorders.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy